• 1
    Godard B, ten Kate L, Evers-Kiebooms G, Ayme S. Population genetic screening programmes: principles, techniques, practices, and policies. European Journal of Human Genetics, 2003; 11: S49S87.
  • 2
    O'Connor AM, O'Brien-Pallas L. Decisional conflict (Specify). In: McFarland GK, McFarlane EA (eds) Nursing Diagnosis & Intervention: Planning for Patient Care, 2nd edn. St. Louis, Missouri: Mosby Inc, 1993: 468478.
  • 3
    Beauchamp TL, Childress JF. Principles of Biomedical Ethics, 3rd edn. New York, NY: Oxford University Press, 1989.
  • 4
    Marteau TM, Dormandy E, Michie S. A measure of informed choice. Health Expectations, 2001; 4: 99108.
  • 5
    van den Berg M, Timmermans DRM, Ten Kate LP, van Vugt JMG, van der Wal G. Are pregnant women making informed choices about prenatal screening? Genetics in Medicine, 2005; 7: 332338.
  • 6
    Bekker H, Thornton JG, Airey CM et al. Informed decision making: an annotated bibliography and systematic review. Health Technology Assessment (Winchester, England), 1999; 3: 1156.
  • 7
    Irwig L, McCaffery K, Salkeld G, Bossuyt P. Informed choice for screening: implications for evaluation. British Medical Journal, 2006; 332: 11481150.
  • 8
    Jepson RG, Hewison J, Thompson AGH, Weller D. How should we measure informed choice? The case of cancer screening. Journal of Medical Ethics, 2005; 31: 192196.
  • 9
    Dormandy E, Michie S, Hooper R, Marteau TM. Informed choice in antenatal Down syndrome screening: a cluster-randomised trial of combined versus separate visit testing. Patient Education & Counseling, 2006; 61: 5664.
  • 10
    Michie S, Dormandy E, Marteau TM. The multi-dimensional measure of informed choice: a validation study. Patient Education & Counseling, 2002; 48: 8791.
  • 11
    Brown K, Dormandy E, Reid E, Gulliford M, Marteau T. Impact on informed choice of offering antenatal sickle cell and thalassaemia screening in primary care: a randomized trial. Journal of Medical Screening, 2011; 18: 6575.
  • 12
    Dormandy E, Tsui EYL, Marteau TM. Development of a measure of informed choice suitable for use in low literacy populations. Patient Education & Counseling, 2007; 66: 278295.
  • 13
    Dormandy E, Bryan S, Gulliford MC et al. Antenatal screening for haemoglobinopathies in primary care: a cohort study and cluster randomised trial to inform a simulation model. The Screening for Haemoglobinopathies in First Trimester (SHIFT) trial. Health Technology Assessment, 2010; 14: 1160.
  • 14
    Smith SK, Trevena L, Simpson JM, Barratt A, Nutbeam D, McCaffery KJ. A decision aid to support informed choices about bowel cancer screening among adults with low education: randomised controlled trial. British Medical Journal, 2010; 341: c5370.
  • 15
    Steckelberg A, Hülfenhaus C, Haastert B, Mühlhauser I. Effect of evidence based risk information on “informed choice” in colorectal cancer screening: randomised controlled trial. British Medical Journal, 2011; 342: d3193.
  • 16
    van den Bergh KAM, Essink-Bot ML, van Klaveren RJ, de Koning HJ. Informed participation in a randomised controlled trial of computed tomography screening for lung cancer. European Respiratory Journal, 2009; 34: 711720.
  • 17
    Mullen PD, Allen JD, Glanz K et al. Measures used in studies of informed decision making about cancer screening: a systematic review. Annals of Behavioral Medicine, 2006; 32: 188201.
  • 18
    Evans R, Joseph-Williams N, Edwards A et al. Supporting informed decision making for Prostate Specific Antigen (PSA) testing on the web: an online randomized controlled trial. Journal of Medical Internet Research, 2010; 12: e27.
  • 19
    Korfage IJ, van Ballegooijen M, Wauben B, Habbema JDF, Essink-Bot M-L. Informed choice on Pap smear still limited by lack of knowledge on the meaning of false-positive or false-negative test results. Patient Education and Counseling, 2011; 85: 214218.
  • 20
    World Health Organisation. Proposed International Guidelines on Ethical Issues in Medical Genetics and Genetic Services. Geneva: World Health Organisation, 1998.
  • 21
    Khoury MJ, McCabe LL, McCabe ERB. Genomic medicine – population screening in the age of genomic medicine. New England Journal of Medicine, 2003; 348: 5058.
  • 22
    Gourounti K, Sandall J. Do pregnant women in Greece make informed choices about antenatal screening for Down's syndrome? A questionnaire survey. Midwifery, 2008; 24: 153162.
  • 23
    Jaques AM, Sheffield LJ, Halliday JL. Informed choice in women attending private clinics to undergo first-trimester screening for Down syndrome. Prenatal Diagnosis, 2005; 25: 656664.
  • 24
    Rowe HJ, Fisher JRW, Quinlivan JA. Are pregnant Australian women well informed about prenatal genetic screening? A systematic investigation using the multidimensional measure of informed choice [see comment]. Australian & New Zealand Journal of Obstetrics & Gynaecology, 2006; 46: 433439.
  • 25
    Wynter KH, Rowe HJ, Fisher JR, Lee M, Quinlivan JA. Are adolescents' decisions about prenatal screening for Down syndrome informed? A controlled, prospective study. Journal of Pediatric and Adolescent Gynecology, 2011; 24: 2934.
  • 26
    Nagle C, Gunn J, Bell R et al. Use of a decision aid for prenatal testing of fetal abnormalities to improve women's informed decision making: a cluster randomised controlled trial ISRCTN22532458. BJOG: An International Journal of Obstetrics and Gynaecology, 2008; 115: 339347.
  • 27
    Ajzen I. The theory of planned behavior. Organizational behavior and human decision processes, 1991; 50: 179211.
  • 28
    Gourounti K, Sandal J. The validation and translation of multidimensional measure of informed choice in Greek. Midwifery, 2011; 27: 170173.
  • 29
    Wakefield CE, Meiser B, Homewood J et al. A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk. Breast Cancer Research and Treatment, 2008; 107: 289301.
  • 30
    Wakefield CE, Meiser B, Homewood J et al. Randomized trial of a decision aid for individuals considering genetic testing for hereditary nonpolyposis colorectal cancer risk. Cancer, 2008; 113: 956965.
  • 31
    Wakefield CF, Meiser B, Homewood J et al. A randomized trial of a breast/ovarian cancer genetic testing decision aid used as a communication aid during genetic counseling. Psycho-oncology, 2008; 17: 844854.
  • 32
    Fu YH, Kuhl DP, Pizzuti A et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell, 1991; 67: 10471058.
  • 33
    Verkerk AJ, Pieretti M, Sutcliffe JS et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell, 1991; 65: 905914.
  • 34
    Kronquist K, Sherman S, Spector E. Clinical significance of tri-nucleotide repeats in Fragile X testing: a clarification of American College of Medical Genetics guidelines. Genetics in Medicine, 2008; 10: 845.
  • 35
    Nolin SL, Lewis FA III, Ye LL et al. Familial transmission of the FMR1 CGG repeat. American Journal of Human Genetics, 1996; 59: 12521261.
  • 36
    Berkenstadt M, Ries-Levavi L, Cuckle H, Peleg L, Barkai G. Preconceptional and prenatal screening for fragile X syndrome: experience with 40,000 tests. Prenatal Diagnosis, 2007; 27: 991994.
  • 37
    McConkie-Rosell A, Finucane B, Cronister A, Abrams L, Bennett RL, Pettersen BJ. Genetic counseling for fragile X syndrome: updated recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 2005; 14: 249270.
  • 38
    Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in fragile X study–preliminary data. American Journal of Medical Genetics, 1999; 83: 322325.
  • 39
    Hill MK, Archibald AD, Couns GDG, Cohen J, Metcalfe SA. A systematic review of population screening for fragile X syndrome. Genetics in Medicine, 2010; 12: 396410.
  • 40
    Metcalfe S, Jacques A, Archibald A et al. A model for offering carrier screening for fragile X syndrome to nonpregnant women: results from a pilot study. Genetics in Medicine, 2008; 10: 525535.
  • 41
    Archibald AD, Jaques AM, Wake S, Collins VR, Cohen J, Metcalfe SA. “It's something I need to consider”: decisions about carrier screening for fragile X syndrome in a population of non-pregnant women. American Journal of Medical Genetics. Part A, 2009; 149A: 27312738.
  • 42
    Flouris A, Hawthorne G, Aitken MA, Gaff C, Metcalfe SA. Development of a questionnaire for evaluating genetics education in general practice. Journal of Community Genetics, 2010; 1: 175183.
  • 43
    Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). British Journal of Clinical Psychology, 1992; 31: 301306.
  • 44
    Streiner DL, Norman GR. Health Measurement Scales: A Practical Guide to Their Development and Use, 2nd edn. Oxford; New York: Oxford University Press, 1995.
  • 45
    Pett MA, Lackey NR, Sullivan JJ. Making Sense of Factor Analysis: The Use of Factor Analysis for Instrument Development in Health Care Research. Thousand Oaks, CA: Sage Publications Inc, 2003; 3–5: 141143.
  • 46
    StataCorp LP. Stata Statistical Software. College Station. 12.0 ed. Texas: StataCorp LP, 2011.
  • 47
    van den Berg M, Timmermans DRM, ten Kate LP, van Vugt JMG, van der Wal G. Informed decision making in the context of prenatal screening. Patient Education and Counseling, 2006; 63: 110117.
  • 48
    Archibald AD, McClaren BJ. Perceived relevance of genetic carrier screening: observations of the role of health-related life experiences and stage of life in decision making. Journal of Community Genetics, 2012; 3: 4754.
  • 49
    Bryant LD, Green JM, Hewison J. The role of attitudes towards the targets of behaviour in predicting and informing prenatal testing choices. Psychology & Health, 2010; 25: 11751194.
  • 50
    McCormack L, Treiman K, Bann C et al. Translating medical evidence to promote informed health care decisions. Health Services Research, 2011; 46: 12001223.
  • 51
    Allen JD, Othus MKD, Hart A, Mohllajee AP, Li Y, Bowen D. Do men make informed decisions about prostate cancer screening? Baseline results from the “Take the Wheel” trial. Medical Decision Making, 2011; 31: 108.
  • 52
    Dawson NV, Weiss R. Dichotomizing continuous variables in statistical analysis. Medical Decision Making, 2012; 32: 225226.